SINCE the discovery of Dicumarol by Linik in 1939, miany papers have appeared oni the use of anticoagulants in various thromboemnbolie cionditions. Marple and Wrightl have provided ani extensive review of the literature up to 1950 coveringfl theoretical aspects of the problem and results of treatment in many, chiefly acute, colnditions. Beginniing in 1944 with the initial report of Nichol and Faweett,2 long-term, or prophylactic, anticoagulant therapy has received increasing attention in different thromboembolic conditions. In 1957, Bjerkelunid3 reviewed the many published reports on long-term therapv in mnyocardial infaretion. The few papers oln treatment in cerebral vascular disease were reviewed in the report of the Second Confercnice on Cerebral Vascular Diseases, edited by Wright and Millikan.4 Despite the developinig abundaniee of reports the prophylactic value of long-term anticoagulant therapy remains equivocal, largely because maniy of the studies lack suitable conitrols and do not lend themselves to statistical analysis. Although most of the reports have found the treatment beneficial, they do not make clear the degree to which this is the ease; nior are indications for treatmeent or discontinuanee entirely agreed upon. Furthermore, there are not yet adequate data with which to estimate the probability of recurrence and death during and after discontinuing treatmenit. The present report attempts to clarify these questionis.
Rationale of Anticoagulant Therapy
Whether or niot a hypercoagulable state exists in thromboembolic coniditions, a local surface or disease process must be present, From the Schools of Medicine and Public Health, lUniversity of Minnesota, Minneapolis, Minn. 354 silee clotting does inot occnir throughout the enitire vascular system but only ill local areas. The experimental and elinical evidence suggests that under normal eircumstaniees the intima maintains a niegative charge from a colntinuous layer of negatively charged hepariin-like inaterial. With intimal damage there presumably is a reversal or reduction of the niegative charge; this alteration is associated with the disappearance of heparin-like properties and with the appearance of cephalin-like material at the surface, givinig rise to platelet stickiness. As a result, thrombosis may occur when the blood components are in a condition to respond to these iintimal changes. If such a hypothesis is correct, heparini would be valuable in affecting the intimnal cells and in neutralizing any eirculatilg, active plasma thromboplastin (factor V or ac-globulin). Heparin might also prevent platelet stickiness and, in large doses, might exert an antithrombic effect. Antiprothrombin drugs also may decrease activity of plasma thromboplastin component; they are known to decrease the activitv of plasma thromboplastiin aiitecedemnt (factor VII), which is necessary for the normal action of tissue thromboplas-tilI.
In coroniary andcl cerebral arterial diseases atherosclerosis is generally recognized as the primary process. Considerable disagreemenit. however, exists as to the pathogenesis of atheroselerosis. 1Until recently the general opinion has beenl that atheroselerosis begilns as a degenerative change with a deposition of eholesterol in the deep layers of the initima followed by fibrous tissue proliferation. Recently Duguid and Robertson0I have revived interest in the old theory of Rokitanskyj who stated that atheroina was the result of excessive deposition of blood derivatives, partieu-Circulation, Volume XXI, March 1960 larly fibrin, on the inner surface of the arteries. Some experimental evidence has subsequently supported this view, i.e., that fibrinous thickening of the initima with narrowing of the lumen can result from gradual organization of thrombi in the arteries. Thus thrombogenic intimal changes may ultimately form a site for secondary thrombotic deposition. Continuous and prolonged anticoagulant therapy may therefore be of signifieance in preventing further development of atherosclerosis as well as in preventing thrombosis at the site of an atherosclerotic plaque. [8] [9] [10] [11] Experimental evidence also indicates that anticoagulant therapy increases the natural tendency to recanalization of occluding thrombi. 12 A wide variety of eircumstanees have been suggested as causes of the hypothetical state of hypercoagulability. These inelude a postprandial hypercoagulability that is apparently related to the intake of saturated fatty acids. It is believed that such a condition would be minimized by prolonged anticoagulant therapy.5 Thrombolysis must also be considered ill the pathogenesis of thrombosis. Grieg and Rundle13 have demonstrated in vitro a marked reduction in fibrinolysis in the plasma of subjects after a high-fat meal; they have found, however, that the lipemia resulting from the ingestion of unsaturated fatty acids does not inhibit fibrinolysis. If postprandial inhibition of fibrinolysis does occur, then the other factors involved in thrombogenesis should be minimized by the use of anticoagulants.
Methods and Material
The present study is an evaluation of the results of long-term anticoagulant therapy in a group of 336 patients encountered in a stable urban midwestern practice with various thromboembolic conditions, classified as follows: 1 Anticoagulant therapy (90 per cent of paitients received Dicumarol, Danilone, or Cumopyran) was usually started in the hospital, although in sonie instances it was initiated in ambulatory patients.
Prothrombin times as a rule were measured daily during hospitalization and less frequently on longterm programs with outpatients. With imiost longtermn patients, prothrombin time determiiinations were made every 3 weeks with the Quick 1-stage method. A "therapeutic prothronibin time" has been arbitrarily defined as falling between 18 and 35 seconds. The control was almost always 12 seeonds or less.
The study is entirely a retrospective evaluation and is in no sense a planned experiment. Accordingly, various therapeutic measures in addition to anticoagulant treatment were used.
The present report compares the rates of first nonfatal recurrence in persons on continuous anticoagulant therapy with the rates after discontinuing therapy in the entire group. It further presents the mortality rates, and describes the pattern of recurrence after discontinuance of therapy in persons with brief, intermediate, and prolonged initial periods of continuous therapy.
To manage the large and varied assortment of data a code sheet of 80 items was filled out for each patient; the data on this sheet were then transferred to IBM punch cards for sorting analysis. The items recorded include the initial diagnosis; various biographical data (sex, age, occupation, ethnic group, height and weight, family history, past history of prior thromboembolic and other significant diseases); laboratory data; electrocardiographic nleasurements; appropriate timie miieasurements; the nature and dates of first and subsequent recurrences during therapy and after therapy; the incidence and nature of hemiorrhagic complications; the stability of office and hospital prothrombin times; subsequent clinical status of the patient; and the incidence, time, and nature of death.
All thromboembolic episodes occurring after the episode leading to inclusion in the study were considered to be recurrences. Episodes of prolonged angina were classed as recurrences, even though the diagnosis of infarction could not always be made. Likewise, transient attacks of cerebral arterial insufficieney were included, despite the fact that some of these may not have been thromlboembolic in origin.
Three timle-periods were used in the evaluation. The first, called the "total period of observation," was measured from the date on which the patient was first seen for the episode leading to inelusioin in the study until the date on which the patient's Circulation, Volume XXI, March 1960 This period was then subdivided into an initial period called the "duration of continuous therapyand a subsequent period called the 'period of observation after first discontinuance."
The "first nonfatal recurrence on conitinuous therapy" was measured on the time-scale dating from the date of inclusion in the study and corresponding to the scale used for "duration of continuous therapy." The "first nonfatal recurrence after discontinuing therapy" was measured fromi the date of the first discontinuance of therapy and corresponds to the time-scale covering the "period of observation after the first discontinuance." The death time-scales a,re similar.
For easy interpretationi, comiiparison, and determnination of the statistical significance anid reIliability of the results, the method of construeting survivorship tables14 has been chosen. This mnethod consists in determining rates of death or first recurrence at successive periods of time. Then the estimated number of persons per original 1,000 with nonrecurrence or survival at successive time periods can be determined. The standard errors of these estimates of the number of survivors were used to compute the significance of differences noted in various groups.15 (See Appendix.)
Comparison of the Groups The genieral outline of anticoagulant therapy for the entire sample of 336 cases is shown in figure 1. Patients who died in the first month (acute death) were excluded from the study. as were those who received only heparin (no continuous treatment). For simplicity's sake, the term "treated group" is used to deseribe the 308 patients who had a period of continuous treatment; the term "discontinued group" to describe the 203 observed after discontinuing treatment (including 4 patients whose treatment was very brief); lIONG-TERM ANTICOAGULANT THERAPY episodes and of angina pectoris, and a larger percentage of prior abnormal electrocardiograms. The incidence of hypertension, cardiac decompensation, and diabetes is similar in the 2 groups.
Thus, the 109 patients in the never-diseontinued group are clearly shown to be poorer risks by virtue of age, sex, prior history, aind associated pathologic conditions. Moreover, this greater severity of involvement in those who were continued on treatment was noted uniformly for each disease category. 16' 17 The patients in the discontinued group did in fact show a lesser tendency to have thromboembolic recurrences during their period of continuous therapy. Compared with the patients whose therapy was never discontinued, they had a lower incidence of recurrence during the first year on therapy and no recurrences during the subsequent course of treatment.
The Use of the Discontinued Group as a "Control" Comparison of the rates of first nonfatal recurrence during therapy and after discontinuing therapy raises the question of the validity of using the discontinued group as a "ceontrol" to be compared with the treated group. In the present study the use of the discontinued group as a control can be justified in several ways:
1. The discontinued group originally comprised two thirds of the treated group, and it thus serves as a control for itself (tables 1 to 4).
2. The never-discontinued group (the remaining third of the treated group) has been shown to be actually a poorer risk group than the discontinued group.
3. The incidenee of recurrence among the members of the discontinued group while on their initial continuous treatment was not higher than that for those who remained on treatment.
4. Unfavorable response to treatment and complications of treatment were not significant factors in determining discontinuance. The reasons for discontinuing treatment were Circulation, Volume XXI, March 1960 indication over (121 instances), initiative of patient (35 instanees), other diseases or operation (30 instances), and complication of treatment (13 instances). Of the 13 who discontinued because of complications, 4 died and 2 had nonfatal recurrences in the first year after discontinuance. These numbers are not large enough to affect the first-year recurrence and death rates substantially.
Results

Incidence of First Nonfatal Recurrence
None of the patients in the discontinued group received anticoagulant therapy after its discolntinuation, in the absence of recurrence. Thus in the time periods being considered the entire treated group was on therapy, and the entire discontinued group was off therapy.
During the first year of continluous therapy, there were 23 nonfatal recurrenees; of these 16 occurred with subtherapeutic prothrombin times and 7 with therapeutic prothrombin times. In the second year there were 2 recurrences with subtherapeutic prothrombin times, and, thereafter, none occurred with subtherapeutic prothrombin times.
The pattern of first nonfatal recurrence during therapy and after discontinuing therapy is shown in table 5. The first year on treatment is subdivided into 4 smaller units to record changes in rate during that period. The rates are based on the ratio of the nulni- ber with no recurrelnce during the tiime period to the number exposed to the risk of haviing a first nonfatal recurrence. It is important to note that a patient who has had a first nonfatal recurrence may remain on therapy, but no longer be exposed to the risk of having a first nonfatal recurrence, having already had onle. Such a patient would of course continue to be exposed while on therapy to the risk of death.
The tinued. The lower section of table 5 preselnts the rate of first nonfatal recurrence after discontinuiiig therapy. The first year after discontinuing therapy is inot subdivided. Approximatelv 821 persons would have had ino recurrenlce after 60 months on continuous therapy as compared with 396 with 11o recurreiice 60 inouths after having discontinued therapy. Figure 2 presents the data froin table a inl graphic formn. The curves show the niumber of personis who could be expected to have no recurrenice at the successive intervals indicated on the time scale. The brackets enclose +1 standard error. The rate of recurrenee in the group o01 treatment is inlitially high anid rapidly dimiinishes durinig the first fe w months, the curve becominginearly horizontal by the end of the first vear. The rate renlainis low throughout the first 5 years. The drop at the end of the curve is associated with a very small number of cases, and the standard error of the estimate is therefore greater. The curve for the recurrenice rate ill persons who discontiniued therapy is also high initially. but, by conltrast, it remains high throughout the period of observation.
Effects of Different Durations of Continuous Treatment on the Recurrence Rates after Discontinuing Therapy
The patients in whom treatmelnt was discontinued were separated into those whose Circulation, Volume 
Figure 3
Numnber of persons with no recurrence of original hypothetical groups of 1,000 (ordinate) for number of years (abscissa) after discontinuing therapy in groups with different durations of initial treatment.
initial treatment was brief (0 to 3 months), intermediate (3 to 12 months), and long (12 to 60 months).* The rate of first nonfatal recurrence after discontinuing therapy was determined for each of the 3 groups ( fig. 3 ).
The date of onset of the prior continuous therapy was used as the zero time point, and the rate curves begin at the average time of discontinuance for the 3 groups. The 3 curves merge at 40 per cent still free of recurrence in 51/2 years. The recurrence rate for patielts who were treated longer initially is somewhat goreater after discontinuance.
Death Rates during Treatment and after
Discontinuation
In comparison of the mortality in the treated and discontinued groups it must be noted that the discontinued group includes a substantial number of patients whose therapy had been resunied after a nonfatal recurrence.
As far as mortality is conieerned, then, the discontinued group is to be viewed as a group on intermittent therapy. Eighteen deaths occurred in the group on continuous treatment. Of these, 1 occurred with a subtherapeutic prothrombin time, 2 occurred with a prothrombin time greater *The curve for the group with brief iniitial treatment is based oIn 118 cases exposed to the risk of having a first nonfatal recurrence after discontinuing therapy. The intermediate group curve is based on 40.5 cases, and the more prolonged group curve is based on 24.5 cases. than 40 seconds (the prothronibin tinme determination nearest to the time of the fatal episode), and 15 occurred with a prothrombin tinme in the therapeutic range. There were 46 deaths in the discontinued group.
The mortality rates are shown in figure 4 .
Since the range of +1 standard error overlaps at each anniversary (brackets), no significant difference exists between the 2 curves. The group on continuous treatment has a soniewhat lower death rate for the first 5 years, after which the rates are about the same. At the end of 5 years, approximately 737 persons of an original 1,000 would have survived in the group on colntinuous therapy. In the group observed after discontinuing therapy, 702 of 1,000 would have survived. The larger percentage of more serious cases in the group treated for prolonged periods probably affects its later mortality adversely.
Effects and Complications of Treatment
When treatinent was initiated during hospitalization, a prothrombini time of 20 seconds or more was achieved by the third morning of hospitalizatioin in 92 per cent of the cases. During hospitalization the prothrombin time was in the therapeutic range 80 per cent or more of the time in 80 per cent of the cases. The percentage of prothrombin tinmes in the therapeutic range was computed for each patient who had had office prothrombin determinations. The average of these per-Circulation, Volume XXI, March 1960 in the average stability of prothrombin conitrol was observed with longer or briefer periods of treatment.
Hemorrhagic complications were observed in 19 per cent of the patients, with 12 per cent having only 1 episode, 5 per cent having 2 episodes, and 3 per cent having 3 or more episodes. Of a total of 95 bleeding episodes, 78 were considered minor, and 17 were considered severe. Two deaths occurred in patients whose prothrombin times were greater than 40 seconds. Discussion The pattern of first nonfatal recurrence in persolns on continuous therapy was described in table 5. This table can be thought of also as presenting the probability of remaining free from subsequent recurrenee. Two important :factors must be considered in viewing the first recurrence rates on continuous therapy: (1) the tendency to recurrence is very strong during the immediate post-thrombotic period; and (2) anticoagulant therapy requires some time to become established. During the first month the recurrence rate is 3.6 per cent. Thereafter, the rate decreases to an average of 1 the likelihood of further nonfatal recurrence remains small. During the first year on treatmenit a subtherapeutic prothrombin time was frequently associated with recurrence. Despite the relative frequency of subtherapeutic prothrombiin times in later years, associated recurrence alnost never took place.
Thus, the rate of recurrence in patients on continuous therapy appears to be initially high. The early high rate suggests the importance of maintaining therapeutic prothrombin time levels during the first several months. Coincident with the establishment of anticoagulant therapy, the recurrence rate becomes lower rapidly and approaches zero for several years. At the end of 5 years, 821 of the original hypothetical 1,000 receiving treatment continuously would have had lno recurrence (table 5) .
The pattern of recurrence in patients who discontinued therapy is quite different. In this group the recurrence rate is high during the first year after discontinuing therapy, namely, 20.9 per cent or about 1.74 per cent per month.
This average rate per month is not so high as the rate observed for the first month on con-Circulation, Volume XXI, March 1960 tinuous therapy; but in the discontinued group the rate of recurrence remains high, with no sign of the tendency to level out observed in the group on continuous therapy. Thus, at the end of 5 years, only 396 persons of 1,000 who had discontinued treatment would still be free of recurrence. The difference in rate of first nonfatal recurrence has been shown to be statistically significant throughout the period of observation. (See Appendix.)
To date there has been no useful guide to the indications for discontinuing aniticoagulant therapy. The decision to discontinue should be made when the patient is presumably as safe off therapy as he is on therapy. The curves in figure 2 show clearly that the tendency to recurreinee after discontinuance is not favorably affected by a longer duratioln of initial continuous therapy. There appears to be no significant differenee between the rates of recurrenee after discontinuance following brief (0 to 3 moniths) and intermediate (3 to 12 months) durations of iniitial therapy.
Following more prolonged initial therapy (average of 3 years) the rate of recurrence after discontinuanee actually appears to be higher. It is true that the latter group conitains a higher percentage of coronary cases and a smaller pereentage of venious thromboembolic cases.
These data inidicate that mainitaining aniticoagulant therapy does not arrest the underlying disease process and that upon discontinuance, the thrombotic tendeniey again becomes manifest and eveni shows a tendeniec to "catch up." Thus, the evidenlce suggests that there is no timne wheni it is safe to discontinue anticoagulaint therapy in the more serious thromboenibolic diseases.
Appendix
The estimates of numibers of sur.vivors or ulonrecurrors per 1,000 (table 5) , involve statistical variations.
The staindard errors of these estimiiates can be used inl the following ways: 1. The initerval equal to the ''iunuber of survivors plus or imiinus twice the standard error"' will cover the ''true" or ''long-run average" of the number of survivors 95 per cent of the time. 2. The standard errors can be used to determine Circulktion, Volume XXI, March 1960 'Time measurecl from clate of inclusion in study. 2Time measured from date of discontinuance.
the significaniee of differenlces between 2 groups. To test the hypothesis that the treated group has a larger number of noairecurrors than the discontinued group, the observed difference in the number with no recurrence is comipared wvith the square root of the sum of the squared estiimiates of the standard errors. If the observed difference is greater than 1.65 times the latter figure, the tliffereince can be conlsidered significant at the 5 per cenit level. Thus, to compare the treated group wArith the discoiitiiuued group at 1 year, for example, the differeniee in the observed niumber of cases w-ith no recurreince is 81 (table 5), while 1.65 times the square root of the sum of the squares of the estimates of the standard errors is only 66; therefore the diference is significaint. Since a bancl of 1 standard error has beeni marked off in the graphs around each estimate of the number of persons with Ino recurrence, and these standard errors for the 2 groups are similar at corresponding time intervals, the differences can be considered significant if the THOMES, SCALLEN, SAVAGJE bands are separated by 0.3 or imiore of 1 stanidarid error. Thus, the treated group has a significantly greatei iiumber with Ino recurrIence at the end of the first year and throughout the period of observation ( fig. 2) .
In interpreting the statistical analysis 2 technica, points should be made. Iiisofar as the discontinued group represents a (randomn) sanmple of the treatedli group, the estimates of rates and differences of rates in the various groups are unbiased; i.e., the averages of these rates for large saimples would correspond to the populatioin values. The standard deviations for a single group are valid whenever the estimate of the rate is unbiased. In comparing 2 groups with the use of the standard deviations, the results are correct with Ino fuIrther assunmptions wyhen the groups are disjoint, e.g., never-discontinued and discontinued. To use the standard deviattioi.s when the groups are not disjoinit, e.g., coiitiiiuous therapy and discontinued therapy, onie would need to assume exponential survival distributioins.1.
